2 days Ago By ABMN Staff
KLP Kapitalforvaltning AS bought a new position in Fulgent Genetics, Inc. ( NASDAQ:FLGT – Free Report ) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 3,100 shares of the company’s stock, valued at approximately $57,000.
Other hedge funds have also bought and sold shares of the company. State Street Corp increased its holdings in Fulgent Genetics by 1.4% during the 3rd quarter.
State Street Corp now owns 793,545 shares of the company’s stock worth $17,244,000 after purchasing an additional 10,868 shares in the last quarter. Geode Capital Management LLC lifted its stake in Fulgent Genetics by 2.7% during the 3rd quarter.
Geode Capital Management LLC now owns 502,869 shares of the company’s stock valued at $10,930,000 after acquiring an additional 13,320 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Fulgent Genetics by 113.
2% during the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after purchasing an additional 179,477 shares in the last quarter.
Barclays PLC lifted its position in shares of Fulgent Genetics by 22.6% during the 3rd quarter. Barclays PLC now owns 174,855 shares of the company’s stock worth $3,800,000 after buying an additional 32,250 shares in the last quarter.
Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Fulgent Genetics by 803.2% in the 4th quarter.
Connor Clark & Lunn Investment Management Ltd. now owns 125,957 shares of the company’s stock worth $2,326,000 after buying an additional 112,011 shares during the last quarter. Institutional investors and hedge funds own 48.
06% of the company’s stock. Insider Buying and Selling at Fulgent Genetics In other news, CFO Paul Kim bought 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average price of $15.
96 per share, for a total transaction of $1,596,000.00. Following the transaction, the chief financial officer now directly owns 348,282 shares of the company’s stock, valued at $5,558,580.
72. This represents a 40.28 % increase in their position.
The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink . Insiders own 31.76% of the company’s stock.
Fulgent Genetics Stock Up 9.6 % Wall Street Analysts Forecast Growth A number of analysts recently commented on FLGT shares. StockNews.
com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, March 5th. Piper Sandler reduced their target price on shares of Fulgent Genetics from $22.00 to $16.
00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Read Our Latest Research Report on FLGT Fulgent Genetics Company Profile ( Free Report ) Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Articles Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. ( NASDAQ:FLGT – Free Report ).
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter ..
